Latest Kaiser Health News Stories
Called “Ready, Set, PrEP,” the federal program will provide medication that can reduce the chances of getting AIDS to at-risk patients who don’t have insurance.
Open enrollment for the Affordable Care Act’s marketplace plans is halfway over and, so far, the number of people signing up is down, but not dramatically. Meanwhile, Congress and President Donald Trump can’t seem to agree on what to do about teen vaping, drug prices or “surprise” medical bills. And Democrats lurch to the left on abortion. Paige Winfield Cunningham of The Washington Post, Kimberly Leonard of the Washington Examiner and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more health news.
The final directive drew swift responses from the hospital and insurance industries. The Trump administration also released a proposed rule that would require health insurers to spell out for all services beforehand just how much patients may owe for their out-of-pocket costs.
It’s November, do you know where your HHS spending bill is? Still stuck in Congress. Meanwhile, lawmakers move ahead on restricting tobacco products for youth while the administration’s proposal is MIA. Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more health news from the week. Also, Rovner interviews Dan Weissmann, host of the podcast “An Arm and a Leg.”
Nearly 8 in 10 Americans say the cost of prescription drugs is unreasonable, but the odds look grim for Congress to pass significant pricing legislation this year.
KHN’s Shefali Luthra discusses the recent Trump administration lawsuit regarding the HIV-prevention drug Truvada.
She has led the way, but all the candidates need to come clean about their health care proposals.
The agency approved Gilead’s “game changer” hepatitis C cure, bypassing concerns raised by its own federal inspectors.
Katie West, an American health researcher who has lived in Germany the past three years, hasn’t mastered the language and misses her family. But not having to worry about the cost of her lifesaving medication makes it OK.
Manufacturers of lucrative drugs say they’re offering discounts off the high sticker prices ― but taxpayers footing the big bills might never know what the state is paying or if it’s getting a good deal.
House Democrats start legislative work on House Speaker Nancy Pelosi’s prescription drug pricing bill; health is again a featured player in the Democratic presidential candidate debate; and courts around the country hold up President Donald Trump’s health agenda. This week, Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists recommend their favorite health stories of the week.
California Gov. Gavin Newsom signed off on an array of health care bills that will significantly affect the lives of Californians, including many college students, pregnant women, schoolchildren and dialysis patients.
Pharmaceutical companies raised the wholesale cost of their drugs by a median of nearly 26% from 2017 to early 2019, according to California’s first-ever report stemming from a new drug price transparency law. Prices for generic drugs rose nearly 38% during that time.
For more than a decade, customers used the online plan finder to compare dozens of policies. Yet after a redesign of the website, the search results no longer list which plan offers a customer the best value. Federal officials say it will be fixed before enrollment begins next week.
Washington is abuzz with impeachment talk, but what impact would such a move have on congressional action on prescription drug prices and surprise bills? Also, a study out this week shows that health insurance costs for both employers and workers continue to rise. This week, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
The reasons behind one particular shortage of a therapy known as IVIG are complicated, stemming from increased demand and the medication’s long production window.
The House speaker announced her plan for lowering drug prices, which includes negotiations between drugmakers and federal health officials.